SCHEMBL994264

SCHEMBL994264

CN1CCC(Nc2[c]nccc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
RET P07949 1/20 0.39
IKBKB O14920 1/20 0.39
HRH4 Q9H3N8 2/20 0.39
BRD4 O60885 1/20 0.37
ATAD2 Q6PL18 1/20 0.37
IDH2 P48735 1/20 0.37
KDM1A O60341 1/20 0.37
KAT2B Q92831 2/20 0.37
NOS2 P35228 1/20 0.36
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCND3 P30281 1/20 0.36
CDK6 Q00534 1/20 0.36
DYRK1A Q13627 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
CDC7 O00311 1/20 0.36
DBF4 Q9UBU7 1/20 0.36
EHMT2 Q96KQ7 1/20 0.35
AXL P30530 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12471296 0.85 KDM4E (0.34) CDK4
SCHEMBL2068159 0.82 KDM4E (0.40)
SCHEMBL3512656 0.74 POLB (0.46) POLBIKBKBIDH2KDM1AKAT2B
SCHEMBL2301577 0.70 HRH4 (0.46) POLBRETIKBKBHRH4KAT2B
SCHEMBL27717981 0.70 SIGLEC9 (0.54) POLBIDH2
SCHEMBL13162840 0.69 KDM4E (0.60) POLBRETIKBKBHRH4IDH2
SCHEMBL12440506 0.69 NOS2 (0.62) POLBRETIKBKBHRH4KDM1A
SCHEMBL933179 0.69 SMN1; SMN2 (0.41)
SCHEMBL14980372 0.68 POLB (0.64) POLBIKBKBHRH4BRD4ATAD2
Hydrochloric Acid SCHEMBL27710837 0.68 NOS2 (0.60) POLBRETIKBKBHRH4KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3072890-B1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy MEI PHARMA INC (US) 2018-10-17 EP disclosed
EP-3072890-A1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy MEI Pharma, Inc. (US) 2016-09-28 EP disclosed
US-8486939-B2 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy PATHWAY THERAPEUTICS INC. (US) 2013-07-16 US disclosed
EP-2532659-A1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy Pathway Therapeutics, Inc. (US) 2012-12-12 EP disclosed
US-20110009405-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY PATHWAY THERAPEUTICS LIMITED (NZ) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009405-A1 PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY TYMP, TYMS, CCNI POLB 165/4885RET 1471/4885IKBKB 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.